Clinical Trials on Wasting Syndrome

Total 36320 results

King's College Hospital NHS Trust

Not yet recruiting

Gastric Residual Volumes in Infants Fed at 4 and 6 Hours Prior to General Anaesthesia

Pediatric ALL | Anesthesia | Fasting

United Kingdom
Philipps University Marburg Medical Center

Completed

Influence of Expectations on Rumination

Depression

Germany
National Institute of Diabetes and Digestive and...

Completed

Does Metabolic Syndrome Exist in Anorexia Nervosa?

Anorexia Nervosa | Metabolic Syndrome

United States
Massachusetts General Hospital
Tiny Blue Dot Foundation

Not yet recruiting

Examining the Impact of Heated Yoga on Mindfulness and Rumination (RHYME)

Depression
Groupe Francophone des Myelodysplasies
Bristol-Myers Squibb; AbbVie

Recruiting

Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes

Untreated Myelodysplastic Syndrome

France
Case Comprehensive Cancer Center

Recruiting

CPX-351 Therapy for MDS After Hypomethylating Agent Failure

Myelodysplastic Syndrome (MDS)

United States
Novartis Pharmaceuticals

Terminated

A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants (STIMULUS-MDS3)

Myelodysplastic Syndrome (MDS)

France, Spain, Belgium, Italy, Greece, Hungary, Germany
Weill Medical College of Cornell University
Novartis Pharmaceuticals

Completed

MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions (T2*MRI)

Myelodysplastic Syndrome (MDS)

United States
Incyte Corporation

Terminated

Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)

MDS (Myelodysplastic Syndrome)

United States
Chinese Society of Hematology
Harbin Institute of Hematology & Oncology

Unknown

Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study (MD-CHINA)

Myelodysplastic Syndrome (MDS)
Asociación Andaluza de Hematología y Hemoterapia

Completed

Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia (ABRAZA)

Myelodysplastic Syndrome (MDS)

Spain
Genzyme, a Sanofi Company

Terminated

Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome (RISE)

Myelodysplastic Syndrome (MDS)

Germany, United Kingdom, France, Netherlands
Heinrich-Heine University, Duesseldorf

Terminated

Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome (VALENA)

Myelodysplastic Syndrome MDS

Germany
Telik

Terminated

Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

United States
Telik

Completed

Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)

United States
Seagen Inc.

Completed

A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome (MDS)

United States
Laboratorios Sophia S.A de C.V.

Completed

Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Ultra Preservative Free (087LATAMFIV) (087LATAMFIV)

Dry Eye Syndrome

Mexico
Columbia University
National Institute on Aging (NIA)

Completed

Neural Predictors of Social Emotion Regulation Training

Emotions | Rumination

United States
zhang shoulong
Changhai Hospital; Jinan Military General Hospital

Recruiting

Biomarker and Imaging Package Study in Immune Effector Cell-Associated Neurotoxicity Syndrome

Immune Effector Cell Associated Neurotoxicity Syndrome

China
AbbVie
Genentech, Inc.

Active, not recruiting

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona)

Myelodysplastic Syndrome (MDS)

United States, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Puerto Rico, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, Hungary
Amphivena Therapeutics, Inc.

Completed

A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes

Myelodysplastic Syndrome (MDS)

United States
Celgene

Completed

Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

China
Amgen

Completed

Darbepoetin Alfa MDS Companion Protocol

Myelodysplastic Syndrome (MDS)

Belgium
Novartis Pharmaceuticals

Terminated

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) (GEPARD)

Myelodysplastic Syndrome (MDS)

Germany
Telik

Completed

Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)

United States
Sao Jose do Rio Preto Medical School
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

The Effects of Nutritional Intervention in Participants With Eating Disorders.

Binge-Eating Disorder | Eating Disorders | Eating Behavior | Eating Disorder | Binge Eating Disorder Associated With Obesity

Brazil
Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

Japan
Fondazione Italiana Sindromi Mielodisplastiche-ETS

Recruiting

Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care (FISiM-NGS-MDS)

MDS (Myelodysplastic Syndrome)

Italy
Novartis Pharmaceuticals

Active, not recruiting

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Myelodysplastic Syndrome (MDS)

United States
Fujifilm Pharmaceuticals U.S.A., Inc.

Withdrawn

A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Safety of ON 01910.Na in Patients With Myelodysplasia

Myelodysplastic Syndrome (MDS)

United States
Telik

Terminated

Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

United States
Oncology Specialties, Alabama

Terminated

Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)

United States
Thomas Jefferson University
AbbVie

Recruiting

Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome

Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic Syndrome

United States
Phramongkutklao College of Medicine and Hospital

Completed

Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients

Dengue | Dengue With Warning Signs | Dengue Shock Syndrome

Thailand
University of North Carolina, Chapel Hill
The Hilda & Preston Davis Foundation; Global Foundation for Eating Disorders

Completed

Uniting Couples In the Treatment of Eating Disorders (UNITE) (UNITE)

Eating Disorder | Binge-eating Disorder

United States
University of Oklahoma
National Institute on Aging (NIA)

Recruiting

The Effect of Intermittent Fasting on Brain Health

Aging | Intermittent Fasting

United States
St. Boniface Hospital

Completed

Pre-habilitation Program for Elective Coronary Artery Bypass Graft Surgery Patients

Patients Waiting for Elective Coronary Artery Bypass Graft Surgery

Canada
Universitat Jaume I

Unknown

Efficacy and Effectiveness of a Self-applied Online Program to Promote Resilience and Coping Skills in College Students

CORE Condition | Healthy Lifestyle Psychoeducational Program | Waiting List Control

Argentina, Mexico, Spain
Dexa Medica Group

Completed

Bioequivalence Study of 4 mg Glimepiride Tablet

Glimepiride BE Study in Healthy Volunteers Under Fasting Condition

Indonesia
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions

Canada
Par Pharmaceutical, Inc.
Phoenix International Life Sciences, Inc.

Completed

Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions

Canada
Scripps Health
J. Craig Venter Institute

Completed

Biomarker Monitoring in TP53 Mutation Carriers

Li-Fraumeni Syndrome | Hereditary Cancer Syndromes | TP53 Gene Germline Mutation Carrier

United States
GlaxoSmithKline

Completed

The Effect of a Nutritional Supplement on Post Prandial Glucose and Lipids in an Adult Population

Impaired Fasting Glucose

India
US Department of Veterans Affairs

Completed

Increasing Evidence-based Clinical Practices in VA

Hand Washing

United States
Par Pharmaceutical, Inc.
BASi Clinical Research Unit

Completed

Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions

United States
Par Pharmaceutical, Inc.
AAI Clinic

Completed

Bioavailability Study of Tramadol/APAP Tablets Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioequivalence Study Doxycycline Tablets and Monodox Capsules Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions

Canada
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions

Canada
University of Wisconsin, Madison

Terminated

Botox for the Treatment of Chronic Exertional Compartment Syndrome

Compartment Syndrome of Leg

United States

Clinical Trials on Wasting Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations